Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases

Miaomiao Liu; Hong Guo; Zhongyuan Li; Chenghua Zhang; Xiaoping Zhang; Qinghua Cui; Jingzhen Tian

doi:10.3389/fnagi.2020.601603

Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases

Front Aging Neurosci. 2020 Oct 23:12:601603. doi: 10.3389/fnagi.2020.601603. eCollection 2020.

Authors

Miaomiao Liu¹, Hong Guo², Zhongyuan Li¹, Chenghua Zhang¹, Xiaoping Zhang^{1

3}, Qinghua Cui^{1

3}, Jingzhen Tian^{1

3}

Affiliations

¹ College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
² Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
³ Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, China.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease with a high incidence rate and complicated pathogenesis. Currently, all anti-AD drugs treat the symptoms of the disease, and with currently no cure for AD. Flavonoid containing natural products, Myricetin (MYR) and Dihydromyricetin (DMY), are abundant in fruits and vegetables, and have been approved as food supplements in some countries. Interestingly, MYR and DMY have been reported to have anti-AD effects. However, the underlying anti-AD mechanism of action of MYR and DMY is complex with many facets being identified. In this review, we explore the benefit of MYR and DMY in AD patients from a molecular level. Their mechanism of action are discussed from various aspects including amyloid β-protein (Aβ) imbalance, neuroinflammation, dyshomeostasis of metal ions, autophagy disorder, and oxidative stress.

Keywords: Alzheimer’s disease; Dihydromyricetin; Myricetin; mechanism of action; natural product.

Publication types

Review